MedTrace Logo

TETRAVI Expanded Access Program

NCT07104591 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-08-05

No results posted yet for this study

Summary

This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the treatment of persistent or recurrent infections with EBV, CMV, adenovirus, or BK virus in pediatric patients being treated in Texas who have received allogeneic stem cell transplants and have no other suitable therapeutic options.

Conditions

  • Epstein-Barr Virus Infection
  • Cytomegalovirus Infections
  • Adenovirus Infection
  • BK Virus Infection
  • JC Virus Infection
  • Viral Infections Post-Transplant
  • Post-Allogeneic Stem Cell Transplant Complications

Interventions

BIOLOGICAL

HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)

Banked, partially HLA-matched virus-specific T cells (VSTs) directed against EBV, CMV, adenovirus, and BK virus.

Sponsors & Collaborators

  • Baylor College of Medicine

    lead OTHER

Principal Investigators

  • John Craddock, MD · Baylor College of Medicine

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07104591 on ClinicalTrials.gov